clonidine and Chronic Pain
clonidine has been researched along with Chronic Pain in 21 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Chronic Pain: Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Eperisone, an analgesic and centrally acting muscle relaxant has been in use for the treatment of low back pain (LBP)." | 8.93 | Clinical efficacy and safety of eperisone for low back pain: A systematic literature review. ( Ali Kareem, S; Bavage, S; Dhadde, SB; Durg, S, 2016) |
" Clonidine is better than zopiclone for insomnia treatment in chronic pain patients." | 8.12 | Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. ( Bamgbade, DO; Bamgbade, OA; Fadire, A; Mumporeze, L; Murphy-Akpieyi, O; Soni, NK; Tai-Osagbemi, J, 2022) |
"Chronic pain is a major health issue and most patients suffer from spontaneous pain." | 5.42 | Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice. ( Feng, ZH; Li, XY; Liu, L; Mei, SH; Wang, M; Wang, Y; Wang, YJ; Zuo, ZX, 2015) |
"Clonidine is a presynaptic alpha-2-adrenergic receptor agonist that has been used for many years to treat hypertension and other conditions, including chronic pain." | 5.22 | Topical clonidine for neuropathic pain in adults. ( Dobrogowski, J; Garlicki, J; Jakowicka-Wordliczek, J; Serednicki, WT; Wordliczek, J; Woron, J; Wrzosek, A; Zajaczkowska, R, 2022) |
"Eperisone, an analgesic and centrally acting muscle relaxant has been in use for the treatment of low back pain (LBP)." | 4.93 | Clinical efficacy and safety of eperisone for low back pain: A systematic literature review. ( Ali Kareem, S; Bavage, S; Dhadde, SB; Durg, S, 2016) |
"Clonidine is a presynaptic alpha-2-adrenergic receptor agonist used for many years to treat hypertension and other conditions, including chronic pain." | 4.91 | Topical clonidine for neuropathic pain. ( Dobrogowski, J; Jakowicka-Wordliczek, J; Wordliczek, J; Woron, J; Wrzosek, A, 2015) |
" Clonidine is better than zopiclone for insomnia treatment in chronic pain patients." | 4.12 | Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. ( Bamgbade, DO; Bamgbade, OA; Fadire, A; Mumporeze, L; Murphy-Akpieyi, O; Soni, NK; Tai-Osagbemi, J, 2022) |
"Multimodal IT treatment with morphine, bupivacaine and clonidine is effective and safe for treating refractory cancer pain in the terminal phase of disease." | 3.85 | Multimodal intrathecal analgesia in refractory cancer pain. ( Kallewaard, JW; Kramp-Hendriks, BJ; Mastenbroek, TC; Vonk, JM, 2017) |
"Clonidine is a central alpha(2)-agonist antihypertensive used widely for opioid/alcohol withdrawal, attention deficit hyperactivity disorder and chronic pain management." | 3.83 | Intrathecal Clonidine Pump Failure Causing Acute Withdrawal Syndrome With 'Stress-Induced' Cardiomyopathy. ( Graudins, A; Lee, HM; Ruggoo, V, 2016) |
" An antiallodynic topical combination of apraclonidine + lisofylline was also found to effectively relieve depressed postocclusive reactive hyperemia in CPIP rats (N = 61) and to increase formazan production in postischemic tissues (skin and muscle) (N = 56)." | 3.80 | Topical combinations to treat microvascular dysfunction of chronic postischemia pain. ( Abaji, R; Coderre, TJ; Laferrière, A; Ragavendran, JV; Tsai, CY, 2014) |
"Chronic pain may be accompanied by hyperalgesia and allodynia, and analgesic interventions may reduce these hypersensitivity phenomena." | 2.80 | Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome. ( Eisenach, JC; North, J; Rauck, RL, 2015) |
"The frequency of neuropathic pain was assessed using the Douleur Neuropathique 4-question survey (DN4) in the first and second postoperative months." | 2.78 | Effect of the addition of clonidine to locally administered bupivacaine on acute and chronic postmastectomy pain. ( Abdel-Ghaffar, HS; Mohamed, SA, 2013) |
"It is essential to find good postoperative pain control strategies that facilitate early mobility, early recovery, and early hospital discharge with minimal side effects on the mother and infant." | 2.66 | Strategies of analgesic treatment after cesarean delivery. Current state and new alternatives. ( Arroyo-Fernández, FJ; Calderón Seoane, JE; Torres Morera, LM, 2020) |
"Chronic pelvic pain is a common and debilitating condition; its aetiology is multifactorial, involving social, psychological and biological factors." | 2.50 | Non-surgical interventions for the management of chronic pelvic pain. ( Cheong, YC; Smotra, G; Williams, AC, 2014) |
"Recent awareness that chronic pain may occur after childbirth has prompted clinicians and researchers to investigate this topic." | 2.49 | Chronic pain after childbirth. ( Bollag, L; Landau, R; Ortner, C, 2013) |
"Chronic pain is a major health issue and most patients suffer from spontaneous pain." | 1.42 | Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice. ( Feng, ZH; Li, XY; Liu, L; Mei, SH; Wang, M; Wang, Y; Wang, YJ; Zuo, ZX, 2015) |
Research
Studies (21)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 17 (80.95) | 24.3611 |
2020's | 4 (19.05) | 2.80 |
Authors
Authors | Studies |
---|---|
Wu, YJ | 1 |
Guernon, J | 1 |
McClure, A | 1 |
Luo, G | 1 |
Rajamani, R | 1 |
Ng, A | 1 |
Easton, A | 1 |
Newton, A | 1 |
Bourin, C | 1 |
Parker, D | 1 |
Mosure, K | 1 |
Barnaby, O | 1 |
Soars, MG | 1 |
Knox, RJ | 1 |
Matchett, M | 1 |
Pieschl, R | 1 |
Herrington, J | 1 |
Chen, P | 1 |
Sivarao, DV | 1 |
Bristow, LJ | 1 |
Meanwell, NA | 1 |
Bronson, J | 1 |
Olson, R | 1 |
Thompson, LA | 1 |
Dzierba, C | 1 |
Salihovic, M | 1 |
Rijavec, B | 1 |
Muratagic, A | 1 |
Blagus, R | 1 |
Puh, U | 1 |
Bamgbade, OA | 1 |
Tai-Osagbemi, J | 1 |
Bamgbade, DO | 1 |
Murphy-Akpieyi, O | 1 |
Fadire, A | 1 |
Soni, NK | 1 |
Mumporeze, L | 1 |
Serednicki, WT | 1 |
Wrzosek, A | 2 |
Woron, J | 2 |
Garlicki, J | 1 |
Dobrogowski, J | 2 |
Jakowicka-Wordliczek, J | 2 |
Wordliczek, J | 2 |
Zajaczkowska, R | 1 |
Arroyo-Fernández, FJ | 1 |
Calderón Seoane, JE | 1 |
Torres Morera, LM | 1 |
Mastenbroek, TC | 1 |
Kramp-Hendriks, BJ | 1 |
Kallewaard, JW | 1 |
Vonk, JM | 1 |
Hao, D | 1 |
Olugbodi, A | 1 |
Udechukwu, N | 1 |
Donato, AA | 1 |
Maranto, CJ | 1 |
Strickland, NR | 1 |
Goree, JH | 1 |
Landau, R | 1 |
Bollag, L | 1 |
Ortner, C | 1 |
De Andres, J | 1 |
Asensio-Samper, JM | 1 |
Fabregat-Cid, G | 1 |
Cheong, YC | 1 |
Smotra, G | 1 |
Williams, AC | 1 |
Laferrière, A | 1 |
Abaji, R | 1 |
Tsai, CY | 1 |
Ragavendran, JV | 1 |
Coderre, TJ | 1 |
Rauck, RL | 1 |
North, J | 1 |
Eisenach, JC | 1 |
Lee, HM | 1 |
Ruggoo, V | 1 |
Graudins, A | 1 |
Zuo, ZX | 1 |
Wang, YJ | 1 |
Liu, L | 1 |
Wang, Y | 1 |
Mei, SH | 1 |
Feng, ZH | 1 |
Wang, M | 1 |
Li, XY | 1 |
Bavage, S | 1 |
Durg, S | 1 |
Ali Kareem, S | 1 |
Dhadde, SB | 1 |
Park, SC | 1 |
Kim, KH | 1 |
Rossi, M | 1 |
Ianigro, G | 1 |
Liberatoscioli, G | 1 |
Di Castelnuovo, A | 1 |
Grimani, V | 1 |
Garofano, A | 1 |
Camposarcone, N | 1 |
Nardi, LF | 1 |
Jackson, TP | 1 |
Lonergan, DF | 1 |
Todd, RD | 1 |
Martin, PR | 1 |
Mohamed, SA | 1 |
Abdel-Ghaffar, HS | 1 |
Clinical Trials (6)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparison of the Effectiveness of Pulsed Radiofrequency Therapy and Canal Adductor Blockade for Chronic Pain and Functioning in Knee Osteoarthritis[NCT05962463] | 128 participants (Anticipated) | Observational | 2023-12-20 | Not yet recruiting | |||
Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients[NCT05618002] | 150 participants (Anticipated) | Observational | 2022-11-08 | Recruiting | |||
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Topical Gel, 0.1% With Placebo in the Management of Pain Associated With Painful Diabetic Neuropathy[NCT00695565] | Phase 2 | 180 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
A Multicenter Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group Study to Determine the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy[NCT02068027] | Phase 2 | 260 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
Diabetic Neuropathic Pain Topical Treatment- Comparative Study[NCT00661063] | Phase 3 | 200 participants (Anticipated) | Interventional | 2008-04-30 | Not yet recruiting | ||
Comparison of PECS II Block and Combined Serratus Anterior Plane Block to Reduce Acute Pain After Mastectomy[NCT05961735] | 60 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in the Brief Pain Inventory (BPI) Severity Scale at Week 12; mLOCF Imputation
"The Brief Pain Inventory was completed by the subject at clinic visits. The Severity Scale (of 0 to 40) is a composite score, which is the sum of the individual ratings for worst pain, least pain, average pain, and current pain. Each individual question is rated on a scale of 0 to 10, where 0 indicates No Pain and 10 indicates Pain as bad as you can imagine. The change in pain severity is represented as Week 12 minus Baseline, so greater negative numbers represent greater improvement (pain relief)." (NCT00695565)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) |
---|---|
Placebo Gel | -7.9 |
Clonidine Topical Gel (ARC-4558) | -9.6 |
Change From Baseline in the Brief Pain Inventory Functional Interference Scale at Week 12; mLOCF Imputation
"The Brief Pain Inventory was completed by the subject at clinic visits. The Functional Interference Scale (of 0 to 70) is a composite score that measures the degree to which pain interferes with mood, walking, work, relationships, sleep, general activity, and enjoyment of life. The composite score is a sum of the seven individual question scores. Each individual question is rated in reference to pain over the past 24 hours on a scale of 0 to 10, where 0 indicates that pain does not interfere and 10 indicates that pain completely interferes with that function, so lower scores represent better outcomes on this scale.~The change in functional interference is represented as Week 12 minus Baseline, so greater negative numbers represent more improvement." (NCT00695565)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) |
---|---|
Placebo Gel | -15.1 |
Clonidine Topical Gel (ARC-4558) | -17.3 |
Change From Baseline to Week 12 in Overall Quality of Sleep (Chronic Pain Sleep Inventory)
Subjects rated overall quality of sleep over the past week using a 100 mm Visual Analog Scale (VAS) where 100=Excellent and 0=Very Poor. This scale was completed during clinic visits. Change from Baseline is a positive value where quality of sleep improved. (NCT00695565)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) |
---|---|
Placebo Gel | 17.7 |
Clonidine Topical Gel (ARC-4558) | 19.2 |
Change From Baseline to Week 12 in the Anxiety Score of the Hospital Anxiety and Depression Scale (HADS)
The HADS was completed at the Baseline and Week 12 clinic visits. The Anxiety Score component of the HADS includes 7 questions, each with 4 possible answer choices (rated 0 to 3). The composite score is created by adding the scores of the 7 individual questions. A score of 0 to 7 is Normal, 8-10 indicates Mild Anxiety, 11-14 indicates Moderate Anxiety, and 15-21 indicates Severe Anxiety. The change from Baseline is calculated as the Week 12 composite score minus the Baseline composite score. (NCT00695565)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) |
---|---|
Placebo Gel | -0.6 |
Clonidine Topical Gel (ARC-4558) | -1.1 |
Change From Baseline to Week 12 in the Depression Score of the Hospital Anxiety and Depression Scale (HADS)
The HADS was completed at the Baseline and Week 12 clinic visits. The Depression Score component of the HADS includes 7 questions, each with 4 possible answer choices (rated 0 to 3). The composite score is created by adding the scores of the 7 individual questions. A score of 0 to 7 is Normal, 8-10 indicates Mild Depression, 11-14 indicates Moderate Depression, and 15-21 indicates Severe Depression. The change from Baseline is calculated as the Week 12 composite score minus the Baseline composite score. (NCT00695565)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) |
---|---|
Placebo Gel | -0.4 |
Clonidine Topical Gel (ARC-4558) | -0.9 |
Change From Baseline to Week 12 in the McGill Pain Questionnaire (Short Form) Total Score
The McGill Pain Questionnaire asks subjects to rate 15 different kinds of pain, each on a scale of 0 to 3 (0=None, 1=Mild, 2=Moderate, 3=Severe). The total score is a sum of the individual ratings and has a range from 0 to 45, where higher numbers indicate more pain. The 15 types of pain assessed are throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting, tiring-exhausting, sickening, fearful, and punishing-cruel. This scale was completed at the Baseline and Week 12 clinic visits. The change from Baseline is calculated as the Week 12 total score minus the Baseline total score, so greater negative numbers indicate more improvement (pain relief). (NCT00695565)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) |
---|---|
Placebo Gel | -7.3 |
Clonidine Topical Gel (ARC-4558) | -8.7 |
Change From Baseline to Week 12 in the Worst Daily Pain NPRS Score; mLOCF Imputation
"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale. Subjects were asked to record the worst pain in their feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain. The change in pain is represented as Week 12 minus Baseline, so greater negative numbers represent greater improvement (greater pain relief)." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)
Intervention | units on a scale (Mean) |
---|---|
Placebo Gel | -2.1 |
Clonidine Topical Gel (ARC-4558) | -2.5 |
Percentage of Subjects Who Experience at Least 30% Reduction in Average Daily Pain From Baseline; mLOCF Imputation
"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)
Intervention | percentage of subjects (Number) |
---|---|
Placebo Gel | 47 |
Clonidine Topical Gel (ARC-4558) | 52 |
Percentage of Subjects Who Experience at Least 50% Reduction in Average Daily Pain From Baseline; mLOCF Imputation
"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)
Intervention | percentage of subjects (Number) |
---|---|
Placebo Gel | 32 |
Clonidine Topical Gel (ARC-4558) | 37 |
Change From Baseline in Average Daily Pain NPRS Score for Each Week of Treatment; mLOCF Imputation
"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain. A weekly average was calculated from the daily scores for each week. The change in pain is represented as the average weekly score minus Baseline, so greater negative numbers represent more improvement (more pain relief)." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Weeks 1 through 12 (weekly averages)
Intervention | units on a scale (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | |
Clonidine Topical Gel (ARC-4558) | -0.7 | -1.0 | -1.5 | -1.6 | -1.7 | -1.8 | -2.1 | -2.2 | -2.3 | -2.4 | -2.3 | -2.4 |
Placebo Gel | -0.6 | -1.0 | -1.2 | -1.5 | -1.7 | -1.8 | -1.8 | -1.9 | -1.9 | -1.9 | -1.9 | -1.9 |
Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation
"Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS) through Day 84. Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated no pain and a score of 10 was worst possible pain.~The change in pain is represented as Week 12 minus Baseline, so greater negative numbers represent more improvement (more pain relief)." (NCT00695565)
Timeframe: Baseline (average of Days -7 to -1) and Week 12 (Average of Days 78 to 84)
Intervention | units on a scale (Mean) | |
---|---|---|
All subjects | Capsaicin response ≥ 2 | |
Clonidine Topical Gel (ARC-4558) | -2.4 | -2.7 |
Placebo Gel | -1.9 | -1.5 |
Change in Blood Pressure From Baseline to Week 12
Systolic and Diastolic Blood Pressure were measured at clinic visits. This outcome assesses the change in blood pressure from Baseline to Week 12 of treatment. (NCT00695565)
Timeframe: Baseline and Week 12
Intervention | mmHg (Mean) | |
---|---|---|
Change in Systolic BP | Change in Diastolic BP | |
Clonidine Topical Gel (ARC-4558) | 1.0 | 1.0 |
Placebo Gel | -0.4 | -0.2 |
Clinician Global Impression of Change (CGIC) at Week 12
At Week 12, the Investigator was asked to independently rate the subject's total improvement relative to Baseline, whether or not, in their judgement, it was due entirely to study drug treatment or not. Answer choices were: (+3) very much improved, (+2) much improved, (+1) minimally improved, (0) no change, (-1) minimally worse, (-2) much worse, (-3) very much worse. (NCT00695565)
Timeframe: Week 12
Intervention | percentage of subjects (Number) | |||||
---|---|---|---|---|---|---|
Very Much Improved | Much Improved | Minimally Improved | No Change | Minimally Worse | Very Much Worse | |
Clonidine Topical Gel (ARC-4558) | 16.5 | 30.6 | 24.7 | 27.1 | 1.2 | 0 |
Placebo Gel | 5.8 | 38.4 | 27.9 | 25.6 | 2.3 | 0 |
Patient Global Impression of Change (PGIC) at Week 12
At Week 12 the subject was asked to rate their total improvement relative to Baseline, whether or not, in their judgement, it was due entirely to study drug treatment or not. Answer choices were: (+3) very much improved, (+2) much improved, (+1) minimally improved, (0) no change, (-1) minimally worse, (-2) much worse, (-3) very much worse. (NCT00695565)
Timeframe: Week 12
Intervention | percentage of subjects (Number) | |||||
---|---|---|---|---|---|---|
Very Much Improved | Much Improved | Minimally Improved | No Change | Minimally Worse | Very Much Worse | |
Clonidine Topical Gel (ARC-4558) | 21.2 | 27.1 | 28.2 | 22.4 | 1.2 | 0 |
Placebo Gel | 11.8 | 32.9 | 31.8 | 21.2 | 1.2 | 1.2 |
Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score
"The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days]) in the Numeric Pain Rating Scale score assessing the average pain in the past 24 hours in the painful areas of the feet averaged over Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the primary efficacy endpoint, the mean change in pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model." (NCT02068027)
Timeframe: The change from Baseline (averaged over Day -14 to Day -8) to End-of-Treatment (averaged over Days 78 to 84 [±3 days])
Intervention | units on a scale (Mean) |
---|---|
Clonidine Gel 0.1% | -1.6 |
Placebo | -1.6 |
Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores
"The Numeric Pain Rating Scale is a single reading that measures the patients interpretation of their pain on a scale from 0, no pain to 10, worst pain imaginable. The change from baseline can range from -10 to 10. The change from Baseline (worst score from Day -14 to Day -8) to End-of-Treatment (worst score during Days 78 to 84 [±3 days]) in the Numeric Pain Rating Scale score assessing the worst pain in the past 24 hours in the painful areas of the feet from Days 78 to 84 compared to the 7 days at the Baseline Phase (Days -14 to -8). For the endpoint, the change in worst pain intensity from Baseline to Week 12 was analyzed using an analysis of covariance (ANCOVA) model with the Baseline worst pain intensity score serving as a covariate. The statistical model also included treatment, site, site by treatment interaction, and strata. If the site by treatment interaction term was not significant at the 0.1 level, then it was excluded from the model." (NCT02068027)
Timeframe: The change from Baseline (worse over Day -14 to Day -8) to End-of-Treatment (worse over Days 78 to 84 [±3 days])
Intervention | units on a scale (Mean) |
---|---|
Clonidine Gel 0.1% | -1.4 |
Placebo | -1.4 |
Reviews
8 reviews available for clonidine and Chronic Pain
Article | Year |
---|---|
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Topical clonidine for neuropathic pain in adults.
Topics: Adult; Analgesics; Chronic Pain; Clonidine; Diabetic Neuropathies; Humans; Neuralgia; Randomized Con | 2022 |
Strategies of analgesic treatment after cesarean delivery. Current state and new alternatives.
Topics: Acetaminophen; Analgesia, Obstetrical; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia, Epi | 2020 |
Chronic pain after childbirth.
Topics: Acute Pain; Adrenergic alpha-Agonists; Adult; Amines; Analgesics; Anesthetics, Dissociative; Cesarea | 2013 |
Intrathecal delivery of analgesics.
Topics: Analgesics, Opioid; Baclofen; Bupivacaine; Catheters, Indwelling; Chronic Pain; Clonidine; Drug Deli | 2014 |
Non-surgical interventions for the management of chronic pelvic pain.
Topics: Amines; Amitriptyline; Analgesics; Chronic Pain; Clonidine; Contraceptive Agents, Female; Cyclohexan | 2014 |
Topical clonidine for neuropathic pain.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Analgesics; Chronic Pain; Clonidine; | 2015 |
Clinical efficacy and safety of eperisone for low back pain: A systematic literature review.
Topics: Chronic Pain; Clonidine; Humans; Low Back Pain; Pain Measurement; Propiophenones; Treatment Outcome | 2016 |
Intentional intrathecal opioid detoxification in 3 patients: characterization of the intrathecal opioid withdrawal syndrome.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; Clo | 2013 |
Trials
4 trials available for clonidine and Chronic Pain
Article | Year |
---|---|
Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome.
Topics: Adenosine; Adult; Analgesics; Chronic Pain; Clonidine; Complex Regional Pain Syndromes; Cross-Over S | 2015 |
Effect of adding cervical facet joint injections in a multimodal treatment program for long-standing cervical myofascial pain syndrome with referral pain patterns of cervical facet joint syndrome.
Topics: Acetaminophen; Anesthetics, General; Chronic Pain; Clonidine; Codeine; Combined Modality Therapy; Do | 2012 |
Eperisone versus tizanidine for treatment of chronic low back pain.
Topics: Analysis of Variance; Chronic Pain; Clonidine; Drug Therapy, Combination; Female; Humans; Italy; Low | 2012 |
Effect of the addition of clonidine to locally administered bupivacaine on acute and chronic postmastectomy pain.
Topics: Acute Pain; Administration, Topical; Adult; Analgesics; Anesthetics, Local; Breast Neoplasms; Bupiva | 2013 |
Other Studies
9 other studies available for clonidine and Chronic Pain
Article | Year |
---|---|
Discovery of non-zwitterionic aryl sulfonamides as Na
Topics: Administration, Oral; Animals; Chronic Pain; Disease Models, Animal; Dose-Response Relationship, Dru | 2017 |
Effectiveness of Ultrasound-Guided Canal Adductor Blockade for Chronic Pain and Functioning in Knee Osteoarthritis: A Prospective Longitudinal Observational Study.
Topics: Activities of Daily Living; Aged; Analgesics; Anesthetics, Local; Chronic Pain; Clonidine; Disabilit | 2022 |
Clonidine is better than zopiclone for insomnia treatment in chronic pain patients.
Topics: Adult; Azabicyclo Compounds; Chronic Pain; Clonidine; Cross-Over Studies; Humans; Hypnotics and Seda | 2022 |
Multimodal intrathecal analgesia in refractory cancer pain.
Topics: Aged; Analgesics; Bupivacaine; Cancer Pain; Chronic Pain; Clonidine; Female; Follow-Up Studies; Huma | 2017 |
Trauma-induced adiposis dolorosa (Dercum's disease).
Topics: Accidents, Traffic; Adipose Tissue; Adiposis Dolorosa; Adult; Amitriptyline; Analgesics, Non-Narcoti | 2018 |
Combined Superficial and Deep Serratus Plane Block With Bupivacaine, Dexamethasone, and Clonidine in the Treatment of a Patient With Postmastectomy Pain Syndrome: A Case Report.
Topics: Adult; Analgesics; Anesthetics; Bupivacaine; Chronic Pain; Clonidine; Dexamethasone; Drug Therapy, C | 2018 |
Topical combinations to treat microvascular dysfunction of chronic postischemia pain.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Capillaries; Chemistry, Phar | 2014 |
Intrathecal Clonidine Pump Failure Causing Acute Withdrawal Syndrome With 'Stress-Induced' Cardiomyopathy.
Topics: Adrenergic alpha-2 Receptor Agonists; Back Pain; Chronic Pain; Clonidine; Electrocardiography; Equip | 2016 |
Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice.
Topics: Acetylcholinesterase; Alkaloids; Ambenonium Chloride; Analgesics; Animals; Atropine; Behavior, Anima | 2015 |